Journal of Clinical Oncology
Articles in this Issue
Preliminary results of a single-arm, muti-center, prospective clinical study of disitamab vedotin combined with toripalimab and pelvic lymph node dissection for bladder preservation in patients with cT2-4aN0M0 bladder urothelial carcinoma and HER2 expression ≥ 2+ after maximal TURBT.
4592 Background: With the evolution of different treatment eras, the clinical complete response (cCR) rate of bladder canc...
Epidemiological trends and burden of Burkitt lymphoma mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e19083 Background: Burkitt lymphoma (BL), an aggressive B-cell non-Hodgkin lymphoma, shows marked geographic variation, wi...
Convergent PI3K pathway activation and SWI/SNF dysfunction as characteristics of bone-metastatic endometrial cancer.
e17636 Background: Bone metastasis from primary endometrial cancer is rare, reported in fewer than 1% of cases. Despite th...
Neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma: Clinical outcomes and multi-omics analysis from a phase II study.
11561 Background: Neoadjuvant therapy may improve the R0 resection and limb salvage rates in locally advanced soft tissue...
EA6232: A phase II double-blind trial of sulforaphane for therapeutic prevention of melanoma in patients with multiple atypical nevi and a prior history of melanoma.
TPS9611 Background: A significant risk factor for melanoma is presence of atypical/dysplastic nevi (A/DN), and evidence su...
Characterization of patients with head and neck cancer in Argentina.
e23396 Background: Head and neck squamous cell carcinomas (HNSCC) arise from epithelial cells of the lip/oral cavity (OC),...
Risk factors for second primary malignancies (SPM) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A real-world study.
e19022 Background: Patients with CLL/SLL are at increased risk of developing SPM. Identification of key clinical risk fact...
AFP response-based model as a prognostic monitor in unresectable hepatocellular carcinoma management.
e16211 Background: Increasing evidence showed atezolizumab plus bevacizumab (A+B) with transarterial therapies (ABT therap...
Interrogation of fibrolamellar cancer to provide clinically relevant insights into therapeutic vulnerabilities.
10041 Background: Fibrolamellar carcinoma (FLC) is a rare disease that primarily afflicts young adults. Systemic therapy w...
Evaluating value in the age of accelerated approval: A pembrolizumab case study.
11084 Background: The FDA accelerated approval (AA) program was established to expedite approval of promising drugs that m...
Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity: A propensity score matched analysis from a global federated health research network.
5543 Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes an...
Inequities in breast cancer mortality with contributing cardiometabolic disorders among U.S. women aged ≥45 years, 1999–2024.
e12704 Background: While breast cancer survival has improved, cardiometabolic disorders including obesity, diabetes, cardi...
Prion-like dynamics of galectin-3 as a driver of colorectal cancer progression: A digital pathology and computational simulation study of supramolecular aggregation.
e15092 Background: Modern oncology is identifying "onco-prions"—proteins that regulate malignancy through biophysical beha...
Utility of Baveno VII criteria for endoscopy risk stratification prior to systemic therapy in unresectable hepatocellular carcinoma: A real-world Veterans Health Administration experience.
e23388 Background: Patients with unresectable hepatocellular carcinoma (HCC) are at risk for gastroesophageal varices and...
Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study.
9585 Background: Cosibelimab, a high-affinity programmed death ligand-1 (PD-L1)–blocking antibody, is approved by the US F...
From risk to reward: Redefining the role of GLP-1 receptor agonist in pancreatic cancer primary prevention.
e16449 Background: Pancreatic cancer (PC) carries a dismal 5-year survival of < 12%, and no FDA-approved agents exist f...
Multi-omics analysis from the IMMUcan consortium to identify predictors of chemo-immunotherapy response in early-stage triple-negative breast cancer.
2588 Background: Combining PD-1/PD-L1 immune checkpoint blockade (IO) with neoadjuvant chemotherapy (CT) is now a standard...
An LNP-mRNA–based in vivo cell engager as a producer of T macrophage tumor triads in situ for targeted anti-solid tumor therapies.
2547 Background: The solid tumor microenvironment promotes infiltration of myeloid cells, with tumor-associated macrophage...
GP regimen chronomodulated induction chemotherapy combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A phase III, multicenter, randomized controlled study.
TPS6137 Background: Radiotherapy is the primary treatment for nasopharyngeal carcinoma (NPC). Currently, induction chemoth...
Investigating mechanisms of resistance to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC).
4545 Background: Though RCC often exhibits substantial CD8 T-cell infiltration, CD8 abundance does not predict clinical be...
Benchmarking histology foundation models to identify Prosigna high-risk breast cancer patients.
e12572 Background: Currently, a variety of commercial molecular tests, including MammaPrint, Oncotype DX, and Prosigna, ar...
Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.
4060 Background: The ARMANI trial proved the superiority of PTX-RAM switch maintenance over continuation of FOX first-line...
Impact of germline <i>BRCA</i> pathogenic or likely pathogenic variants on fertility potential and reproductive outcomes in young women with breast cancer: A systematic review and meta-analysis.
10606 Background: In young women with a diagnosis of breast cancer (BC), the impact of germline BRCA...
A prospective phase II clinical study of different time-delivered drugs combined with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma.
6061 Background: To compare the effects of combining intensity-modulated radiotherapy administered at different times on t...
Neuroendocrine tumors: Real-world evidence from a national cancer institute in Panama.
e16324 Background: Neuroendocrine tumors (NETs) are rare and heterogeneous malignancies with limited epidemiologic data fr...